期刊文献+

血清内脂素、Vaspin与糖尿病肾病的相关性 被引量:5

Relationship between serum levels of visfatin and vaspin and diabetic nephropathy
下载PDF
导出
摘要 目的 探讨2型糖尿病肾病患者血清内脂素、丝氨酸蛋白酶抑制剂(vaspin)水平与糖尿病肾病的相关性.方法 选择98例2型糖尿病患者,根据尿白蛋白排泄率分为3组:正常蛋白尿组(UAER< 20 μg/min)35例,微量蛋白尿组(UAER 20~200 μg/min)33例,大量蛋白尿组(UAER> 200 μg/min)30例;另选健康体检正常者35例为对照组.采用酶联免疫吸附法(ELISA)检测受检者血清内脂素、vaspin水平,同时测定空腹血糖(FPG)、糖化血红蛋白(HbA1c)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、空腹胰岛素(FIns),并测量体质量指数(BMI)、收缩压(SBP)和舒张压(DBP),比较各组间差异.结果 3组患者血清内脂素水平明显高于对照组,差异有统计学意义(P<0.01);血清vaspin在正常蛋白尿组明显高于对照组、微量蛋白尿组和大量蛋白尿组,差异有统计学意义(P<0.01).内脂素和vaspin分别与BMI、SBP、FPG、HbA1c、LDL-C和FIns呈正相关(P<0.01),与HDL-C呈负相关(P<0.01).结论 血清内脂素水平随着2型糖尿病肾病的发展而逐渐升高,可能参与了2型糖尿病肾病的发生、发展,而vaspin与肥胖、体脂分布以及脂代谢关系密切,可以作为早期2型糖尿病监测指标. Objective To explore the relationship between serum visfatin and vaspin and diabetic nephropathy in type 2 diabetic patients with nephropathy. Methods S98 patients with type 2 diabetes mellitus were divided into three groups according to the urinary albumin excretion rate (UAER): normal albuminuria group (UAER〈 20 μg/min, 35 cases), micro-albuminuria group (UAER 20-200μg/min, 33 cases) and macro-albuminuria group (UAER〉200 μg/min, 30 cases). 35 healthy subjects were included as control group. Serum level of visfatin and vaspin were measured by enzyme linked immunosorbent assay (ELISA). Then, fasting plasma glucose (FPG), HbA1 C, triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and fasting insulin (Fins) levels together with UAER were determined as well. Results The serum levels of visfatin in the diabetic patients were significantly higher than those in control group (P〈 0.01). Serum vaspin levels in the normal albuminuria group were higher than control group, micro-albuminuria group and macro-albuminuria group (P〈O. 01). Serum Ievels of visfatin and vaspin were positively correlated with BMI, SBP, FPG, HbAlc, LDL-C and Fins ( P 〈 0.01 ), while negatively correlated with HDL-L(P 〈 0.01 ). Conelusion The level of visfatin may play a important role in the pathogenesis and development of DN.Serum vaspin 1 evel is related to obesity, body fat distribution, lipid metabolism, so vaspin can be used as indicators to monitor T2DM in early stage.
出处 《实用临床医药杂志》 CAS 2014年第21期31-34,共4页 Journal of Clinical Medicine in Practice
基金 黑龙江省卫生厅科研课题
关键词 糖尿病肾病 内脂素 丝氨酸蛋白酶抑制剂 diabetic nephropathies visfatin vaspin
  • 相关文献

参考文献3

二级参考文献15

  • 1Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, et al. Mefformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008; 57: 1501-1507.
  • 2Gulcelik NE, Karakaya J, Gedik A, Usman A, Gurlek A. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009; 160: 65-70.
  • 3Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372-377.
  • 4Kloting N, Berndt J, Kralisch S, Kovacs E Fasshauer M, Schon MR, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-436.
  • 5Gonzalez-Ortiz M, Martinez-Abundis E. Comparison of several formulas to assess insulin action in the fasting state with the hyperglycemic-hyperinsulinemic clamp technique in healthy individuals. Rev Invest Clin 2003; 55:419-422.
  • 6Bao Y, Lu J, Wang C, Yang M, Li H, Zhang X, et al. Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis 2008; 201: 378-384.
  • 7World Health Organization: definition, diagnosis and classification of diabetes mellitus and its complication. WHO/NCD/NCS 1999: 31-33. (Accessed at http://whqlibdoc. who. int/hq/1999/WHO_NCD_NCS_99. 2.pdj-').
  • 8WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
  • 9Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Bluher M, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008; 93: 247-251.
  • 10Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007; 18: 240-245.

共引文献52

同被引文献61

  • 1江彤,吴爱兵.关于血浆内脏脂肪素与2型糖尿病肾病的探讨[J].中国医疗前沿,2008,3(14):3-4. 被引量:7
  • 2翟莎,周园媛,王战建.腹型肥胖和糖尿病肾病[J].中国医学前沿杂志(电子版),2012,4(9):24-27. 被引量:7
  • 3武阳丰,马冠生,胡永华,李艳平,李贤,崔朝辉,陈春明,孔灵芝.中国居民的超重和肥胖流行现状[J].中华预防医学杂志,2005,39(5):316-320. 被引量:567
  • 4Karnpe K, Sieber J, Orellana JM, et al. Susceptibility of podocytes to palmitic acid is regulated by fatty acid oxidation and inversely depends on aeetyl-CoA carboxylases Physiol,2014,306(4) : F401-F409.
  • 5Chen HiM, Zheng CX, Gao Q, et al protein is associated with proteinuria (9) : e45691. 1 and 2. Am J Physiol Renal Heart-type fatty acid binding in obesity. PLoS One, 2012,7.
  • 6Karlsson C, Rak J, I.arsson J. RNA interference screening to detect targetable molecules in hematopoietic stem cells. Curr Opin Hematol, 2014,21(4) :283-288.
  • 7Binas B, Darmeberg H, MeWhir J, et al.Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEB J, 1999,13(8) :805-812.
  • 8Kamijo-lkemori A,Sugaya T,Matsui K,et al.Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology ( Carlton ) , 2011, 16 ( 6 ) : 539-544.
  • 9Guan Y, Zhang Y, Schneider A, et al. Peroxisome proliferator-aetivated receptor-gamma activity is associated with renal mierovaseulature.Am J Physiol Renal Physiol,2001,281 (6) :F1036-F1046.
  • 10Oyama Y, Takeda T, Hama H, et al. Evidence for megalin-mediated proximal tubular uptake of L-FABP, a carrier of potentially nepbrotoxie.Iab Invest, 2005,85 ( 4 ) : 522 -531.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部